WO2000027840A1 - Process for racemization - Google Patents

Process for racemization Download PDF

Info

Publication number
WO2000027840A1
WO2000027840A1 PCT/HU1999/000076 HU9900076W WO0027840A1 WO 2000027840 A1 WO2000027840 A1 WO 2000027840A1 HU 9900076 W HU9900076 W HU 9900076W WO 0027840 A1 WO0027840 A1 WO 0027840A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
vii
mol
process according
organic
Prior art date
Application number
PCT/HU1999/000076
Other languages
French (fr)
Inventor
Mária Bakonyi
Tiborné BAI
Zsolt DOMBRÁDY
Katalin GÁSPÁR
Attila Supic
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Priority to AU12896/00A priority Critical patent/AU1289600A/en
Priority to AT99956254T priority patent/ATE303377T1/en
Priority to BR9914883-8A priority patent/BR9914883A/en
Priority to EP99956254A priority patent/EP1129087B1/en
Priority to CA002347853A priority patent/CA2347853C/en
Priority to US09/830,930 priority patent/US6670486B1/en
Priority to JP2000581018A priority patent/JP4598276B2/en
Priority to DE69927044T priority patent/DE69927044T2/en
Publication of WO2000027840A1 publication Critical patent/WO2000027840A1/en
Priority to US10/718,925 priority patent/US7109356B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Definitions

  • This invention relates to the novel process for the preparation of the racemic
  • an alkali metal alcoholate can favourably be used.
  • Favourable solvents are methanol, ethanol, iso-
  • the reaction is usually performed at a temperature between +20°C and +100°C,
  • the amount of the base is favourably 5-500 mol%, counted for the amount of the
  • optically active compound to be racemized, taking into consideration that when
  • hydrochloride prepared according to example 5. or 6., is mixed with 170 ml of
  • the precipitated material is the salt formed between the
  • dextrorotatory enantiomer of the starting material and D(-)-tartaric acid is filtered off at 50 oc.
  • acetate hydrochloride is suspended in 6,7 ml of 38% aqueous formaline solution
  • reaction mixture is then diluted with 100 ml of 1,2 dichloroethane
  • precipitated crystalline product is filtered off, washed with water and dried.
  • tartarate is suspended in 250 ml of i-propanol. To the mixture 10 g (0.25 mol) of
  • tartarate is suspended in 120 ml of ethanol, to it is added the solution of 20 g (0.5
  • tartarate is suspended in 600 ml of benzene, to it are added 28 g (0.5 mol) of
  • hydrochloride is suspended 120 ml of ethanol, to the mixture 6.2 g (0.11 mol) of
  • tartarate is suspended in 220 ml of toluene, to it are added 22.4 g (0.4 mol) of
  • Fig. 1 shows the general formula (VII) and Fig. 2 shows the synthesis of compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Processing Of Stones Or Stones Resemblance Materials (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Glass Compositions (AREA)

Abstract

The invention relates to the racemization process of the optically active [2-(2-thienyl) ethylamino](2-halogenophenyl)acetamides of general formula (VII) by using basic compounds. The resulting racemic compounds of general formula (VII) can thus be recycled into synthesis of the therapeutically useful compounds of general formula (VI).

Description

PROCESS FOR RACEMIZATION
This invention relates to the novel process for the preparation of the racemic
intermediates of general formula (VII) - wherein X represents halogen atom.
It is known that methyl (2-halogenophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-
yl)acetates and their salts can advantageously be used in the therapy, first of all
owing to their platelet-aggregation-inhibitory and antithrombotic effects.
A particularly favourable representative of these compounds, falling under the
general formula (VI) -wherein X means chloro atom-, is the dextrorotatory methyl
(+)-[(S)-(2-chloroρhenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
hydrogen sulfate], designated with the international non-propriety name (INN)
clopidogrel (European patent application Publication Nr. 099802).
PCT applications Nos PCT/HU98/00046, PCT/HU98/00047 and PCT/HU98/00048
- whose content through this reference is built into the present application - describe
the novel synthesis of the compounds of general formula (VI). In the course of that
synthesis, when the dextrorotatory isomers of compounds of general formula (VII)
are further transformed during the synthesis, the levorotatory isomers of compounds
of general formula (VII) form waste and cause considerable loss.
Our aim was to solve the racemization of the optically active compounds of general
formula (VII) which are not used further in the synthesis and which are of different
optical purity, ensuring thus the recycling of the not used isomer into the synthesis
process. We have found that the individual optically active compounds of general formula
(VII) or their acid addition salts can be transformed into the racemic compounds of
general formula (VII) on the effect of treating them with basic inorganic or organic
compounds. Racemisation of mixtures consisting of various ratio of the levorotatory
and dextrorotatory isomers of compounds of general formula (VII) can also be
solved in this way. In the course of the process, as for inorganic base an alkali metal
hydroxide, as for organic base an alkali metal alcoholate can favourably be used.
Such are for instance, sodium hydroxide, potassium hydroxide, and sodium ethylate
or methylate, potassium ethylate or methylate. The process can be performed in
water-miscible or water-non-miscible organic solvents, as well as in the mixture of
an organic solvent and water. Favourable solvents are methanol, ethanol, iso-
propanol, benzene and toluene.
The reaction is usually performed at a temperature between +20°C and +100°C,
favourably between +40°C and +60°C.
As for starting material, optional acid addition salts of the levorotatory or
dextrorotatory compounds of general formula (VII) can be used, favourable salts are
tartarate and hydrochloride salts.
The amount of the base is favourably 5-500 mol%, counted for the amount of the
optically active compound to be racemized, taking into consideration that when
starting from an acid addition salt, a part of the base will be used for the liberation
of the compound of general formula(VII).
Further details of the invention are demonstrated by the following examples,
without limiting our claims to the content of the examples EXAMPLES
Examples demonstrating: the preparation of the optically active levorotatory
compounds of general formula (VII) to be racemized, furthermore the
preparation of the optically active dextrorotatory compounds of general formula
(VII), and their use in the synthesis of the compounds of general formula (VI).
Example 1.
[2-(2-thienyl)ethylamino](2-chIorophenyl)acetonitrile
104 g ( 1 mol) of sodium bisulfite is dissolved in the mixture of 900 ml of water and
250 ml of ethanol and to the solution 140,6 g (1 mol) o-chlorobenzaldehyde is
added. After a few minutes the aldehyde bisulfite adduct precipitates in the form of
white crystals, while the temperature raises to 40 °C. After 1 hour of stirring 127,2 g
(1 mol) of 2-(2-thienyl)ethylamine is added to the reaction mixture, then it was
stirred at 50 °C for 2 hours. During this time the crystalline aldehyde bisulfite
transforms into an oily material. The mixture is cooled to room temperature and the
solution of 49 g (1 mol) of sodium cyanide in 100 ml of water is added to it. During
the addition the temperature of the reaction mixture raises to 40°C. The mixture is
then stirred at 60 °C till the reaction is completed (1 hour). The oily organic phase
is then extracted with 400 ml of 1,2-dichloroethane, washed to cyanide-free with
2x200 ml of water, traces of 2-(2-thienyl)ethylamine are removed by treatment with
100 ml of 3% hydrochloric acid solution. The dichloroethane phase was dried over
anhydrous sodium sulfate and evaporated in vacuo. The residual fast crystallizing oil is the product. Weight: 260 g (94 %) mp.: 40-41 °C. The product was
identified by elementary analysis, IR spectrum and iH-NMR investigation.
Example 2.
[2-(2-thienyI)ethylamino](2-chlorophenyl)acetonitrile
9,8 g (0,2 mol) of sodium cyanide is dissolved in 70 ml of water and to the solution
first 32,8 g (0,2 mol) of 2-(2-thienyl)ethylamine hydrochloride, then in a period of a
few minutes, the solution of 28,2 g (0,2 mol) of o-chlorobenzaldehyde in 30 ml of
ethanol are added. During the addition the temperature of the mixture raises to 45
°C. The reaction mixture is then stirred at 60 °C for 2 hours, then cooled to room
temperature and diluted with 50 ml of water. The resulting oily product is extracted
with 100 ml of 1,2-dichloroethane, the organic phase is washed to cyanide- free with
2x50 ml of water, the traces of 2-(2-thienyl)ethylamine are removed by treatment
with 20 ml of 3% hydrochloric acid solution. The residual fast crystallizing oil is the
product. Weight: 52 g (94 %) mp.: 40-41 °C. The product was identified as
written in Example 1. Quality of the product is identical to that of the product
prepared according to Example 1.
Example 3.
[2-(2-thienyl)ethylamino] (2-chlorophenyl)acetonitrile hydrochloride
276,7 g (1 mol) of [2-(2-thienyl)ethylamino](2-chlorophenyl)acetonitrile, prepared
according to example 1. or 2., is dissolved in 600 ml of ethanol, to the solution 600 ml of 10% aqueous hydrochloric acid solution is added. Within a few minutes white
crystals precipitate, they are collected, washed with 60 ml of 1 : 1 mixture of 10%
hydrochloric acid and ethanol, then with acetone, and they are dried. Weight: 305 g
(97,4 %), mp.: 153-154 °C. The product was identified by elementary analysis, IR
spectrum and ^H-NMR investigation.
Example 4.
[2-(2-thienyI)ethylamino](2-chlorophenyl)acetonitriIe hydrobromide
13,8 g (0,05 mol) of [2-(2-thienyl)ethylamino](2-chlorophenyl)acetonitrile, prepared
according to example 1. or 2., is dissolved in 30 ml of ethanol, to the solution 40 ml
of 20% aqueous hydrogen bromide solution is added. The product which
precipitates within a few minutes is collected, washed with ethyl acetate and then
they are dried. Weight: 14 g (78,2 %), mp.: 144-145 °C. The product was
identified by elementary analysis, IR spectrum and 1H-NMR investigation.
Example 5.
[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide hydrochloride
Into 1200 ml of methyl acetate 204 g (5.6 mol) of hydrogen chloride gas is
introduced at 15-25 °C, and to the solution are added 221.4 g (0.8 mol) of the [2-(2-
thienyl)ethylamino](2-chorophenyl)acetonitrile, prepared as described in Example
1., and 48 ml (1.2 mol) of methanol. The mixture is stirred at 20-25 °C for 6 hours.
In the course of the reaction first the hydrochloride of the starting "nitrile", then gradually the hydrochloride of the resulting "acid amide" precipitates, in the form of
white crystals. The crystals are collected by filtration, washed with methyl acetate
and dried. Weight: 249 g (94 %) mp.: 231-232 °C.
The product was identified by elementary analysis, IR spectrum and iH-NMR
investigation.
Example 6.
[2-(2-Thienyl)etylamino] (2-chlorophenyl)acetamide hydrochloride
Into 700 ml of ethyl acetate at 0-10 °C 109.8 g (3 mol) of hydrogen chloride gas is
introduced and to the solution 83 g (0.3 mol) of the [2-(2-thienyl)ethylamino](2-
chorophenyl)acetonitrile of formula (I), prepared according to Example 1. or 2.,
and 15 ml (0.37 mol) of methanol are added and the mixture is slowly, in a period of
20 minutes, heated to 45-50 °C. The reaction mixture is then stirred at 45-50 °C for
4 hours, the crystalline product is filtered off at room temperature, washed with
ethyl acetate and dried. Weight: 90.4 g (91 %) op.: 231-232 °C. The quality of the
product is identical to that of the product of Example 5.
Example 7.
[2-(2-Thienyl)ethylamino](2-chloropheι_yl)acetamide
24.8 g (0.075 mol) of [2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide
hydrochloride, prepared according to example 5. or 6., is mixed with 170 ml of
water, then under mild cooling 30 ml of 10% sodium hydroxide solution and 170 ml of 1,2-dichloroethane are added. The phases are separated, the aqueous phase is
extracted with 2x20 ml of 1,2-dichloroethane, the combined organic layer is
evaporated in vacuo. Residue: 22 g, fast crystallizing oil. The crude product is
recrystallized from 80 ml of isopropyl acetate to give 19,5 g of the crystalline base
of formula (VII). Yield: 88,2 %, mp.: 90-92 °C.
The product was identified by elementary analysis, IR spectrum and ^H-NMR
investigation.
Example 8.
Dextrorotatory [2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide
38 g (0.129 mol) of racemic [2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide is
dissolved at 50 °C in 380 ml of isopropanol containing 2% of water and to this
solution is added the 50 °C solution of 10,6 g (0.071 mol) of L(+)-tartaric acid in
230 ml of isopropanol, containing 2% of water. The mixture is stirred at 50 °C for
30 minutes. Thick, white precipitate is formed. To the mixture 3.4 ml (0.09 mol) of
formic acid is added and stirring is continued at 50 °C for 1 hour. The reaction
mixture is then cooled to room temperature, stirred for another hour and the solid
phase is filtered off. The precipitated material is the salt formed between the
levorotatory enantiomer of the starting material and L(+)-tartaric acid, in an
optically slightly contaminated form. Weight: 30 g. Mp.: 167-169°C, after
crystallization from ethanol. Racemization of this salt is described in examples II/4.,
5., 6, 7 and 9. The mother liquor is evaporated in vacuo. The residue ( « 29 g) is taken up in 200 ml of water and 200 ml of 1,2-dichloroethane and neutralized under
stirring with 16 g (0,19 mol) of sodium hydrogen carbonate. The phases are
separated, the aqueous layer is washed with 2x30 ml of 1,2-dichloroethane, the
combined organic layer is extracted with 50 ml of water, dried over anhydrous
sodium sulfate and evaporated in vacuo. Weight: 18 g. The raw product is
recrystallized from 70 ml of ethanol, washed with a small amount of ethanol and
dried. Weight: 12.6 g. Mp.: 122 - 124 °C, [α]2 D = + 69 ° (c = 1, methanol).
Yield: 66,3% calculated on the dextrorotatory enantiomer content of the starting
material. Optical purity: 99 - 100%, usually higher than 98% (determined by
HPLC).
The product was identified by elementary analysis, IR spectrum and XH-NMR
investigation.
By concentration of the filtrate 4 g of racemic starting material can be recovered.
Example 9.
Dextrorotatory [2-(2-thienyl)ethyIamino](2-chlorophenyI)acetamide
3.8 g (0.0129 mol) of racemic [2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide
is dissolved at 50 °C in 38 ml of isopropanol and to this solution is added the 50 °C
solution of 1.06 g (0.0071 mol) of D(-)-tartaric acid in 23 ml of isopropanol. The
mixture is stirred at 50 °C for 30 minutes. Thick, white precipitate is formed. To the
mixture 0.22 ml of formic acid is added and stirring is continued at 50 °C for 30
minutes. The precipitated material, which is the salt formed between the
dextrorotatory enantiomer of the starting material and D(-)-tartaric acid, is filtered off at 50 oc. Weight: 2.5 g. Mp.: 167 - 169 °C (crystallized from ethanol).
Racemization of the levorotatory isomer remaining in the mother liquor is described
in Examples 11/ 1, 2 and 3.
The 2.5 g raw product thus obtained is taken up in the mixture of 10 ml of water and
10 ml of 1,2-dichloroethane and neutralized under stirring with 0.4 g of sodium
hydrogen carbonate. The phases are separated, the organic layer is dried over
anhydrous sodium sulfate and evaporated. The residue is recrystallized from 5 ml
of isopropanol.
Weight: 1.2 g. Mp.: 122 - 124 »C, [α]22D = + 67 o. Yield: 63.3% calculated on the
dextrorotatory enantiomer content of the starting material. The quality of the
product is identical to that of the product obtained in the previous example.
Example 10.
Dextrorotatory methyl [2-(2-thienyI)ethylamino](2-chlorophenyl)acetate-
hydrochloride
In 40 ml of methanol under cooling 11.5 ml (0.215 mol) of 100% sulfuric acid is
dissolved, the solution is heated under reflux conditions for 30 minutes, then after
cooling to room temperature 12.4 g (0.042 mol) of dextrorotatory [2-(2-
thienyl)ehylamino](2-chlorophenyl)acetamide is added and the mixture is heated
under reflux for 6-7 hours, till the end of the reaction. Methanol is distilled off in
vacuo, to the residue 75 ml of 1,2-dichloroethane and 75 ml of water are added, the
mixture is shaken well and the phases are separated. The aqueous phase is extracted
with 2x20 ml of 1,2-dichloroethane, the united organic phase is extracted with 50 ml of 5% sodium hydroxide solution then with 50 ml of water, dried over anhydrous
sodium sulfate. The drying-material is filtered off and 1.5 g (0.041 mol) of dry
hydrogen chloride gas is introduced under cooling into the solution. The precipitated
crystalline product is filtered off, washed with 1,2-dichloroethane and dried.
Weight: 12.1 g, mp.: 185 - 186 oc (decomposition), [ ]2 o = + 107°. Yield: 83%.
Optical purity: in general 99 - 100%.
The product was identified by elementary analysis, IR spectrum and H-NMR
investigation.
Example 11.
(+)-(S)-(2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetic acid
methyl ester hydrochloride salt
6 g (0,017 mol) of dextrorotatory methyl [2-(2-thienyl)ethylamino](2-chlorophenyl)
acetate hydrochloride is suspended in 6,7 ml of 38% aqueous formaline solution
and heated to 60 °C under stirring. The starting material dissolves at 60 °C, the
resulting solution is stirred at that temperature for 30 minutes, till the completion of
the reaction. The reaction mixture is then diluted with 100 ml of 1,2 dichloroethane
and 150 ml of water, and after shaking well, the phases are separated. The aqueous
phase is extracted with 2x30 ml of 1,2-dichloroethane, the united organic phase is
extracted with 100 ml of water, dried over anhydrous sodium sulfate, filtered and
evaporated in vacuo. The residual 6 g of material is dissolved in 30 ml of diethyl
ether, and 0.6 g of dry hydrogen chloride gas is introduced into the solution under
cooling, at room temperature. The precipitated crystalline material is filtered off, washed with ether and dried. Weight: 5,5 g. Mp.: 130 - 132 oc, [α]22 D = + 60 °.
Yield: 90,1%. Optical purity: 99% (by HPLC investigation).
Example 12.
a) (+)-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetic acid
methyl ester (-)-camphorsulfonic acid salt
32 g (0.0994 mol) of (2-chloroρhenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-
yl)acetic acid methyl ester is dissolved in 150 ml of acetone and to the solution 9.95
g (0.0397 mol) of levorotatory 10-camphorsulfonic acid monohydrate is added. The
homogenous reaction mixture is allowed to stay at room temperature. After 48 hours
a few crystals appear. The mixture is concentrated by evaporation to 50 ml and
allowed to stay at room temperature for 24 hours. The resulting crystals are filtered
off, washed with acetone and dried. The crystals thus obtained are dissolved again
in a very small amount (50 ml) of hot acetone and after cooling the crystals are
filtered off, washed with acetone and dried. Thus the title compound is obtained.
Yield: 88%. Mp.: 165 °c. [α]20D = + 24 o (c = 1.68 g/100 ml; methanol).
b) (+)-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetic acid
methyl ester
To the suspension made of 200 g of (+)-(2-chlorophenyl)(6,7-dihydro-4H-
thieno[3,2-c]pyridin-5-yl)acetic acid methyl ester (-)-camphorsulfonic acid salt and
800 ml of dichloromethane is added 800 ml of sodium hydrogene carbonate
solution. After stirring the organic phase is separated by decantation. The (+)-(2- chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetic acid methyl ester is
obtained as a solution in 800 ml of dichloromethane. The solution is dried over
sodium sulfate and the solvent is removed in vacuo.
The (+)-(2-chlorophenyl)(6,7-dihydro-4H-thieno[3 ,2-c]pyridin-5-yl)acetic acid
methyl ester is obtained in the form of colourless oil.
c) (+)-(2-chlorophenyl)(6,7-dihy dro-4H-thieno [3,2-c] py ridin-5-y l)acetic acid
methyl ester hydrogen sulfate salt
The residue obtained in the previous example is dissolved in 500 ml of ice-cold
acetone and to this solution 20.7 ml of concentrated sulfuric acid (93.64%; density
1.83) is added dropwise. The resulting precipitate is separated by filtration, washed
with 1000 ml of acetone and dried in a vacuum oven at 50 °C. Thus 139 g of the
title salt is obtained in the form of white crystals. Mp.: 184 °C, [α]2 = + 55.1 °
(c = 1.891 g/100 ml; methanol).
Examples for the preparation of the racemic compounds of general formula (VII)
starting from the optically active levorotatory compounds of general formula (VII)
obtained in Examples 8 and 9.
Example 1.
29.5 g (0.1 mol) of R-(-)-[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide is
dissolved at 60°C in 120 ml of i-propanol, to the solution 0.8 g (0.02 mol) of
sodium hydroxide is added. The mixture is stirred at 60°C for 20 minutes then it is neutralised with 1.2 ml of acetic acid and concentrated in vacuo to half of its
volume. The solution thus obtained is diluted with 200 ml of water, the resulting
crystalline product is filtered off, washed with water and dried.
Product: racemic [2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide, weight: 28,6
g (97%), mp: 90-92°C.
IR (KBr), cm"1 : 3258, 2862, 1685, 1474, 1445, 1430, 1403, 1387, 1301, 1273,
1247, 1113, 1083, 1049, 1034, 938, 814, 752, 699, 602;
Example 2.
29,5 g (0,1 mol) R-(-)-[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide is
dissolved at 60°C in 120 ml of ethanol, to the solution 0.56 g (0.01 mol) of
potassium hydroxide is added. The mixture is stirred at 60°C for 30 minutes, then it
is neutralized with 0.6 ml of acetic acid and concentrated in vacuo to half of its
volume. The solution thus obtained is diluted with 200 ml of water, the resulting
crystalline product is filtered off, washed with water and dried.
Product: 28,6 g (97%), mp: 90-92OC.
The product is identical with that of the above Example 1.
Example 3.
29,5 g (0,1 mol) R-(-)-[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide is
dissolved at 60°C in 120 ml of ethanol, to the solution 2.1 g (0.03 mol) of sodium
ethylate is added. The mixture is stirred at 60°C for 30 minutes, then it is
neutralized at 40-50°C with 1.8 ml of acetic acid and concentrated in vacuo to half of its volume. The solution thus obtained is diluted with 200 ml of water, the
precipitated crystalline product is filtered off, washed with water and dried.
Product: 28 g (95%), mp: 90-92OC.
The product is identical with that of the above Example 1.
Example 4.
44,5 g (0,1 mol) of R-(-)-[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide L(+)-
tartarate is suspended in 250 ml of i-propanol. To the mixture 10 g (0.25 mol) of
sodium hydroxide is added, it is stirred at 60°C for 30 minutes, then it is neutralized
at 40-50°C with 3 ml of acetic acid. The main bulk of the solvent is distilled off in
vacuo, the residue is diluted with 300 ml of water, the precipitated crystalline
product is filtered off, washed with water and dried.
Product: 28,6 g (97%), mp: 90-92OC.
The product is identical with that of the above Example 1.
Example 5.
The procedure as described in Example 4. is followed, but after the end of the
reaction and neutralization with acetic acid the resulting L(+) tartaric acid di-sodium
salt and sodium acetate are removed by filtration at 60^C. The filtrate is then
evaporated in vacuo, giving the product of the same amount and quality as
described in Example 4. Example 6.
44.5 g (0.1 mol) of R-(-)-[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide L(+)-
tartarate is suspended in 120 ml of ethanol, to it is added the solution of 20 g (0.5
mol) of sodium hydroxide in 120 ml of water. The mixture is stirred at 50°C for 1
hour, the pH is then adjusted to 6.5 by the addition of 10 % aqueous hydrochloric
acid solution and cooled to room temperature. The resulting crystalline product is
filtered off, washed with water and dried.
Product: 26,5 g (90%).
The product is identical with that of the above Example 1.
Example 7.
44.5 g (0.1 mol) of R-(-)-[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide L(+)-
tartarate is suspended in 600 ml of benzene, to it are added 28 g (0.5 mol) of
potassium hydroxide, 72 ml of water and 3 g of tetrabutylammonium bromide. The
resulting two-phase mixture is heated under reflux for 1 hour, then, after cooling it
to room temperature, it is diluted with 500 ml of water. The phases are separated,
the aqueous layer is extracted with 2 x 100 ml of benzene. The united organic
phase is washed with 2 x 150 ml of water, dried over anhydrous sodium sulfate,
treated with fuller earth, filtered and evaporated in vacuo. The residue is suspended
in 100 ml of ethanol, diluted with 400 ml of water, the crystalline product is filtered
off, washed with water and dried.
Product: 28,6 g (97%), op: 90-92OC. Example 8.
33.1 g (0.1 mol) of S-(+)-[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide
hydrochloride is suspended 120 ml of ethanol, to the mixture 6.2 g (0.11 mol) of
potassium hydroxide is added, it is stirred at 60°C for 30 minutes, then it is
neutralized at 40-50°C with 0.6 g of acetic acid, and concentrated in vacuo to half
of its amount. The solution thus obtained is diluted with 200 ml of water, the
resulting crystalline product is filtered off, washed with water and dried.
Product: 28,6 g (97%).
Identification: as described in Example 1.
Example 9.
44.5 g (0.1 mol) of R-(-)-[2-(2-thienyl)ethylamino](2-chlorophenyl)acetamide L(+)-
tartarate is suspended in 220 ml of toluene, to it are added 22.4 g (0.4 mol) of
potassium hydroxide, 60 ml of water and 1 g of tetrabutylammonium bromide. The
resulting two-phase mixture is stirred at 70° C for 30 minutes, cooled to room
temperature, and the phases are separated. The aqueous layer is extracted with 60
ml of toluene, the united organic phases are washed with 2 x 50 ml of water and
evaporated in vacuo. The residue is recrystallized from 40 ml of i-propanol. The
product is filtered off at 0°C, washed with 40 ml of i-propanol, dried at 40-60°C.
Product: 28,6 g (97%), mp: 90-92°C.
Fig. 1 shows the general formula (VII) and Fig. 2 shows the synthesis of compounds
of the general formula (VI).

Claims

Claims
1. Process for the racemization of the optically active compounds of general formula
(VII) - wherein X means halogen atom -, characterized by that, the
optically active compound of general formula (VII) - wherein X means halogen
atom- or its acid addition salt is reacted with an organic or inorganic base.
2. The process according to Claim 1, characterized by that, as for
inorganic base alkali metal hydroxides are applied.
3. The process according to Claim 1, characterized by that, as for
organic base alkali metal alcoholates are applied.
4. The process according to Claim 1, characterized by that, the
racemisation is performed in organic solvent.
5. The process according to Claim 1, characterized by that, the
racemisation is performed in the mixture of an organic solvent and water.
6. The process according to Claim 1, characterized by that, the acid
addition salt of the levorotatory compounds of general formula (VII) is reacted with
the organic or inorganic base.
7. The process according to Claim 1, characterized by that, the acid
addition salt of the dextrorotatory compounds of general formula (VII) is reacted
with the organic or inorganic base.
8. The process according to Claim 1, characterized by that, the process
is carried out at a temperature between +20°C and +100°C.
9. The process according to Claim 1, characterized by that, as for
organic solvents alcohols or aromatic carbohydrates are applied.
10. The process according to Claim 1, characterized by that, the
organic or inorganic base is used in an amount of 5-500 mol%, calculated for the
levorotatory compounds of general formula (VII).
11. The process according to Claim 1, characterized by that, the
organic or inorganic base is used in an amount of 5-500 mol%, calculated for the
dextrorotatory compounds of general formula (VII).
12. The process according to Claim 1, characterized by that, the
racemisation starts from a mixture of the levorotatory compound of general formula
(VII) and the dextrorotatory compound of general formula (VII).
PCT/HU1999/000076 1998-11-09 1999-11-05 Process for racemization WO2000027840A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU12896/00A AU1289600A (en) 1998-11-09 1999-11-05 Process for racemization
AT99956254T ATE303377T1 (en) 1998-11-09 1999-11-05 RACEMIZATION METHOD
BR9914883-8A BR9914883A (en) 1998-11-09 1999-11-05 Process for racemization
EP99956254A EP1129087B1 (en) 1998-11-09 1999-11-05 Process for racemization
CA002347853A CA2347853C (en) 1998-11-09 1999-11-05 Process for racemization of [2-(2-thienyl)ethylamino] (2-halogenophenyl)acetamides
US09/830,930 US6670486B1 (en) 1998-11-09 1999-11-05 Process for racemization
JP2000581018A JP4598276B2 (en) 1998-11-09 1999-11-05 Racemization method
DE69927044T DE69927044T2 (en) 1998-11-09 1999-11-05 PROCESS FOR RACEMICATION
US10/718,925 US7109356B2 (en) 1998-11-09 2003-11-21 Process for racemization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9802586 1998-11-09
HU9802586A HU226421B1 (en) 1998-11-09 1998-11-09 Process for racemizing optically active 2-(2-chlorophenyl)-2-(2-(2-thienyl)-ethylamino)-acetamides

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09830930 A-371-Of-International 1999-11-05
US09/830,930 A-371-Of-International US6670486B1 (en) 1998-11-09 1999-11-05 Process for racemization
US10/718,925 Division US7109356B2 (en) 1998-11-09 2003-11-21 Process for racemization

Publications (1)

Publication Number Publication Date
WO2000027840A1 true WO2000027840A1 (en) 2000-05-18

Family

ID=89997319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1999/000076 WO2000027840A1 (en) 1998-11-09 1999-11-05 Process for racemization

Country Status (12)

Country Link
US (2) US6670486B1 (en)
EP (1) EP1129087B1 (en)
JP (1) JP4598276B2 (en)
AT (1) ATE303377T1 (en)
AU (1) AU1289600A (en)
BR (1) BR9914883A (en)
CA (1) CA2347853C (en)
DE (1) DE69927044T2 (en)
DK (1) DK1129087T3 (en)
ES (1) ES2249038T3 (en)
HU (1) HU226421B1 (en)
WO (1) WO2000027840A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737411B2 (en) 2002-08-02 2004-05-18 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
WO2004074215A1 (en) * 2003-02-03 2004-09-02 Sunil Sadanand Nadkarni Process for preparation of clopidogrel, its salts and pharmaceutical compositions
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
WO2004108665A2 (en) * 2003-04-24 2004-12-16 Sun Pharmaceutical Industries Limited A process for preparation of clopidogrel
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
WO2010046476A1 (en) * 2008-10-24 2010-04-29 Sandoz Ag A process for the preparation of s-clopidogrel
CN110627808A (en) * 2018-06-21 2019-12-31 江苏同禾药业有限公司 Recovery treatment process of clopidogrel hydrogen sulfate splitting mother liquor

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0200438A3 (en) * 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
KR20080055860A (en) * 2006-08-03 2008-06-19 테바 파마슈티컬 인더스트리즈 리미티드 Process for preparing clopidogrel bisulphate
FR2916441B1 (en) * 2007-05-22 2009-08-28 Clariant Specialty Fine Chem PROCESS FOR RACEMIZING OPTICALLY ACTIVE ALPHA-AMINOACETALS
US20100184823A1 (en) 2007-07-05 2010-07-22 Mark Aron Labow dsRNA For Treating Viral Infection
FR2927900B1 (en) * 2008-02-27 2010-09-17 Clariant Specialty Fine Chem PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ALPHA-AMINOACETALS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62252751A (en) * 1986-04-25 1987-11-04 Nitto Chem Ind Co Ltd Racemization of alpha-amino acid amide
US4769486A (en) * 1986-08-26 1988-09-06 Toyo Soda Manufacturing Co., Ltd. Method for racemizing an optically active amino acid
EP0466569A1 (en) * 1990-07-10 1992-01-15 Sanofi Process for preparation of N-phenylacetyl derivative of tetrahydrothieno[3,2-c]pyridine and intermediate of synthesis
WO1998051681A1 (en) * 1997-05-13 1998-11-19 Sanofi-Synthelabo New intermediates and process for the preparation thereof
WO1998051682A1 (en) * 1997-05-13 1998-11-19 Sanofi-Synthelabo New intermediates and process for the preparation thereof
WO1998051689A1 (en) * 1997-05-13 1998-11-19 Sanofi-Synthelabo A new process for the preparation of a pharmacologically active substance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632646A (en) * 1967-05-25 1972-01-04 Uniroyal Inc Succinamides
HU178455B (en) * 1979-07-17 1982-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new 1-substituted-3-cycloalkyl-sulfonyl-pyrrolidine-2,5-dione derivatives
FR2530247B1 (en) * 1982-07-13 1986-05-16 Sanofi Sa NOVEL THIENO (3, 2-C) PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATION
NL8501093A (en) * 1985-04-12 1986-11-03 Stamicarbon METHOD FOR RACEMIZING AN OPTICALLY ACTIVE N-BENZYLIDEENAMINOIC ACID AMIDE

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62252751A (en) * 1986-04-25 1987-11-04 Nitto Chem Ind Co Ltd Racemization of alpha-amino acid amide
US4769486A (en) * 1986-08-26 1988-09-06 Toyo Soda Manufacturing Co., Ltd. Method for racemizing an optically active amino acid
EP0466569A1 (en) * 1990-07-10 1992-01-15 Sanofi Process for preparation of N-phenylacetyl derivative of tetrahydrothieno[3,2-c]pyridine and intermediate of synthesis
WO1998051681A1 (en) * 1997-05-13 1998-11-19 Sanofi-Synthelabo New intermediates and process for the preparation thereof
WO1998051682A1 (en) * 1997-05-13 1998-11-19 Sanofi-Synthelabo New intermediates and process for the preparation thereof
WO1998051689A1 (en) * 1997-05-13 1998-11-19 Sanofi-Synthelabo A new process for the preparation of a pharmacologically active substance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALABASTER R J ET AL: "Synthesis of N-benzyl-3-(S)-(+)-(4-fluorophenyl)-1,4-oxazin-2-one via a crystallisation induced asymmetric transformation", TETRAHEDRON: ASYMMETRY,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 8, no. 3, 6 February 1997 (1997-02-06), pages 447 - 450, XP004094317, ISSN: 0957-4166 *
DATABASE WPI Section Ch Week 198750, Derwent World Patents Index; Class B05, AN 1987-351016, XP002134523 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
US6737411B2 (en) 2002-08-02 2004-05-18 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
US7259261B2 (en) 2002-08-02 2007-08-21 TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság Racemization and enantiomer separation of clopidogrel
EP2168969A2 (en) 2002-08-02 2010-03-31 Teva Pharmaceutical Industries Ltd. Racemization and Enantiomer Separation of Clopidogrel
WO2004074215A1 (en) * 2003-02-03 2004-09-02 Sunil Sadanand Nadkarni Process for preparation of clopidogrel, its salts and pharmaceutical compositions
WO2004108665A2 (en) * 2003-04-24 2004-12-16 Sun Pharmaceutical Industries Limited A process for preparation of clopidogrel
WO2004108665A3 (en) * 2003-04-24 2005-03-24 Sun Pharmaceutical Ind Ltd A process for preparation of clopidogrel
WO2010046476A1 (en) * 2008-10-24 2010-04-29 Sandoz Ag A process for the preparation of s-clopidogrel
CN110627808A (en) * 2018-06-21 2019-12-31 江苏同禾药业有限公司 Recovery treatment process of clopidogrel hydrogen sulfate splitting mother liquor
CN110627808B (en) * 2018-06-21 2022-04-01 江苏同禾药业有限公司 Recovery treatment process of clopidogrel hydrogen sulfate splitting mother liquor

Also Published As

Publication number Publication date
BR9914883A (en) 2001-07-17
DE69927044T2 (en) 2006-06-22
HUP9802586A3 (en) 2001-05-28
US6670486B1 (en) 2003-12-30
DK1129087T3 (en) 2006-01-16
HUP9802586A2 (en) 2001-04-28
JP4598276B2 (en) 2010-12-15
JP2002529462A (en) 2002-09-10
US7109356B2 (en) 2006-09-19
AU1289600A (en) 2000-05-29
CA2347853A1 (en) 2000-05-18
DE69927044D1 (en) 2005-10-06
EP1129087B1 (en) 2005-08-31
ES2249038T3 (en) 2006-03-16
US20040106824A1 (en) 2004-06-03
HU9802586D0 (en) 1999-01-28
HU226421B1 (en) 2008-12-29
EP1129087A1 (en) 2001-09-05
CA2347853C (en) 2009-08-18
ATE303377T1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
EP0981529B1 (en) A new process for the preparation of a pharmacologically active substance
EP0981524B1 (en) New intermediates and process for the preparation thereof
EP1129087B1 (en) Process for racemization
EP0981525B1 (en) (2-(2-thienyl)-ethylamino)-(2-halophenyl)-acetonitriles as intermediates and process for the preparation thereof
EA007907B1 (en) A process for the preparation of clopidogrel
MXPA01004644A (en) Process for racemization
MXPA99010433A (en) New intermediates and process for the preparation thereof
JP4256478B6 (en) Novel process for the preparation of pharmacologically active substances
MXPA99010431A (en) New intermediates and process for the preparation thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 12896

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2347853

Country of ref document: CA

Ref country code: CA

Ref document number: 2347853

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 581018

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004644

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999956254

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09830930

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999956254

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999956254

Country of ref document: EP